MedTrace Logo

Towards Optimal Prescription of Chemotherapy in Prostate Cancer

NCT02512185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 206

Last updated 2020-08-19

No results posted yet for this study

Summary

This study will examine the impact of modern treatments for metastatic Castrate Resistant Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function, objective physical function, and falls. Additionally, the investigators study whether frailty is associated with worse outcomes, and whether it is possible to predict the risk of severe chemotherapy toxicity in older men.

Conditions

Sponsors & Collaborators

  • Prostate Cancer Canada

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Eligibility

Min Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-04-30
Completion
2019-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02512185 on ClinicalTrials.gov